| 1 Exacerbations requiring oral steroids |
3 |
1537 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.40, 1.95] |
| 1.1 Children |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 1.2 Adults |
3 |
1537 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.40, 1.95] |
| 2 Change from baseline in FEV1 |
5 |
2599 |
L (Fixed, 95% CI) |
‐0.02 [‐0.04, 0.01] |
| 2.1 Children |
1 |
556 |
L (Fixed, 95% CI) |
0.0 [‐0.04, 0.04] |
| 2.2 Adults |
4 |
2043 |
L (Fixed, 95% CI) |
‐0.03 [‐0.07, 0.01] |
| 3 Change in FEV1 predicted |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.1 Children |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 3.2 Adults |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 4 Change in FVC |
4 |
2051 |
Mean Difference (IV, Fixed, 95% CI) |
0.00 [‐0.04, 0.04] |
| 4.1 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 4.2 Adults |
4 |
2051 |
Mean Difference (IV, Fixed, 95% CI) |
0.00 [‐0.04, 0.04] |
| 5 Change in clinic PEF |
3 |
1611 |
L/min (Fixed, 95% CI) |
‐1.59 [‐7.43, 4.25] |
| 5.1 Children |
1 |
556 |
L/min (Fixed, 95% CI) |
‐2.5 [‐10.34, 5.34] |
| 5.2 Adults |
2 |
1055 |
L/min (Fixed, 95% CI) |
‐0.45 [‐9.22, 8.31] |
| 6 Change in am PEF |
4 |
2070 |
L/min (Fixed, 95% CI) |
0.41 [‐4.71, 5.53] |
| 6.1 Children |
1 |
556 |
L/min (Fixed, 95% CI) |
‐2.9 [‐11.33, 5.53] |
| 6.2 Adults |
3 |
1514 |
L/min (Fixed, 95% CI) |
2.34 [‐4.10, 8.78] |
| 7 Change in pm PEF |
2 |
1023 |
L/min (Fixed, 95% CI) |
1.30 [‐5.10, 7.70] |
| 7.1 Children |
1 |
556 |
L/min (Fixed, 95% CI) |
‐0.2 [‐8.24, 7.84] |
| 7.2 Adults |
1 |
467 |
L/min (Fixed, 95% CI) |
3.9 [‐6.69, 14.49] |
| 8 Change in rescue medication |
2 |
1085 |
puffs/d (Fixed, 95% CI) |
0.0 [‐0.10, 0.10] |
| 8.1 Children |
1 |
556 |
puffs/d (Fixed, 95% CI) |
0.0 [‐0.14, 0.14] |
| 8.2 Adults |
1 |
529 |
puffs/d (Fixed, 95% CI) |
0.0 [‐0.14, 0.14] |
| 9 Lack of efficacy (exacerbation requiring change in medication) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 9.1 Children |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 9.2 Adults |
0 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 10 Worsening asthma |
3 |
1552 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.61, 1.97] |
| 10.1 Children |
1 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [0.50, 3.14] |
| 10.2 Adults |
2 |
996 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.47, 2.14] |
| 11 Change in asthma‐symptom free days |
1 |
|
% (Fixed, 95% CI) |
Totals not selected |
| 11.1 Children |
1 |
|
% (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 11.2 Adults |
0 |
|
% (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12 Change in quality of life (AQLQ) |
2 |
967 |
AQLQ (Fixed, 95% CI) |
0.17 [0.04, 0.30] |
| 12.1 Children |
0 |
0 |
AQLQ (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.2 Adults |
2 |
967 |
AQLQ (Fixed, 95% CI) |
0.17 [0.04, 0.30] |
| 13 Adverse events |
4 |
2058 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.87, 1.07] |
| 13.1 Children |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 13.2 Adults |
4 |
2058 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.87, 1.07] |
| 14 Candidiasis |
3 |
1529 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.24 [0.10, 0.58] |
| 14.1 Children |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 14.2 Adults |
3 |
1529 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.24 [0.10, 0.58] |
| 15 Pharyngitis |
5 |
2614 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.25 [0.90, 1.74] |
| 15.1 Children |
1 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.49, 2.45] |
| 15.2 Adults |
4 |
2058 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.90, 1.85] |
| 16 Upper resiratory tract infection |
3 |
1613 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.74, 1.47] |
| 16.1 Children |
1 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [0.57, 1.98] |
| 16.2 Adults |
2 |
1057 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.68, 1.56] |
| 17 Headache |
3 |
1613 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.52, 1.49] |
| 17.1 Children |
1 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.44 [0.56, 3.73] |
| 17.2 Adults |
2 |
1057 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.70 [0.37, 1.34] |
| 18 Rhinitis |
2 |
1084 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.61, 1.61] |
| 18.1 Children |
1 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.55, 1.69] |
| 18.2 Adults |
1 |
528 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.41, 2.81] |
| 19 Sinusitis |
2 |
1084 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.41, 1.61] |
| 19.1 Children |
1 |
556 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.56 [0.19, 1.65] |
| 19.2 Adults |
1 |
528 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.43, 2.65] |
| 20 Withdrawals |
5 |
2570 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.79, 1.28] |
| 20.1 Children |
1 |
511 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.47 [0.70, 3.11] |
| 20.2 Adults |
4 |
2059 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.74, 1.24] |
| 21 Withdrawals (adverse events) |
2 |
1059 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.78 [0.66, 4.79] |
| 21.1 Children |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 21.2 Adults |
2 |
1059 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.78 [0.66, 4.79] |
| 22 Withdrawals (lack of efficacy) |
3 |
1570 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.55 [0.86, 7.53] |
| 22.1 Children |
1 |
511 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.02 [0.51, 8.00] |
| 22.2 Adults |
2 |
1059 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.57 [0.59, 21.51] |
| 23 Data not suitable for meta‐analysis (medians) |
|
|
Other data |
No numeric data |
| 24 Change in asthma‐symptom scores |
1 |
|
symptoms (Fixed, 95% CI) |
Totals not selected |
| 24.1 Children |
0 |
|
symptoms (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 24.2 Adults |
1 |
|
symptoms (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
